Neuropsychiatric Manifestations of COVID-19
Advances in Psychiatry and Behavioral Health · 2021
DOI: 10.1016/j.ypsc.2021.05.003 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advances in Psychiatry and Behavioral Health, 2021. Verfasst von Moein Foroughi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Behavioral Sciences, SUNY Downstate Health Sciences University, 450 Clarkson Avenue, Brooklyn, NY 11203, USA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
with COVID-19 with the primary outcomes being the incidence and hazard ratios for psychiatric disorders, dementia, and insomnia during the first 14 to 90 days after a diagnosis of COVID-19 was established. The authors observed that the patients recovering from COVID-19 had a significantly higher rate of psychiatric disorders.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Psychiatry and Behavioral Sciences, SUNY Downstate Health Sciences University, 450 Clarkson Avenue, Brooklyn, NY 11203, USA.
- Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.
- Department of Psychiatry and Human Behavior, Brown University, Providence, RI, USA.
Zitieren
APA
Foroughi, M., Gupta, R., Ganguly, A., Mirza, J., & Fotros, A. (2021). Neuropsychiatric Manifestations of COVID-19. Advances in Psychiatry and Behavioral Health. https://doi.org/10.1016/j.ypsc.2021.05.003
Vancouver
Foroughi M, Gupta R, Ganguly A, Mirza J, Fotros A. Neuropsychiatric Manifestations of COVID-19. Advances in Psychiatry and Behavioral Health. 2021. doi:10.1016/j.ypsc.2021.05.003
BibTeX
@article{Foroughi2021,
author = {Foroughi, Moein and Gupta, Rishab and Ganguly, Amvrine and Mirza, Junaid and Fotros, Aryandokht},
title = {Neuropsychiatric Manifestations of COVID-19},
journal = {Advances in Psychiatry and Behavioral Health},
year = {2021},
doi = {10.1016/j.ypsc.2021.05.003}
}
EUVIMED